Pelizaeus-Merzbacher Disease, Pelizaeus-Merzbacher-Like Disease 1, and Related Hypomyelinating Disorders

Abstract

The purpose of this article is to present contemporary information on the clinical and molecular diagnosis and the treatment of Pelizaeus-Merzbacher's disease (PMD) and related leukodystrophies. Various types of mutations of the X-linked proteolipid protein 1 gene (PLP1) that include copy number changes, point mutations, and insertions or deletions of a few bases lead to a clinical spectrum from the most severe connatal PMD, to the least severe spastic paraplegia 2 (SPG2). Signs of PMD include nystagmus, hypotonia, tremors, titubation, ataxia, spasticity, athetotic movements and cognitive impairment; the major findings in SPG2 are leg weakness and spasticity. A diffuse pattern of hypomyelination is seen on magnetic resonance imaging (MRI) of PMD/SPG2 patients. A similar constellation of signs and pattern of hypomyelination lead to the autosomal recessive disease called Pelizaeus-Merzbacher-like disease 1 (PMLD1) and the less-severe spastic paraplegia 44 (SPG44), caused by mutations of the gap junction protein, gamma-2 gene (GJC2), formerly known as the gap junction protein, α-12 gene (GJA12). Magnetic resonance spectroscopy (MRS) and brainstem auditory evoked potentials (BAEP) may assist with differential clinical diagnosis of PMD and PMLD1. Supportive therapy for patients with PMD/SPG2 and PMLD1/SPG44 includes medications for seizures and spasticity; physical therapy, exercise, and orthotics for spasticity management; surgery for contractures and scoliosis; gastrostomy for severe dysphagia; proper wheelchair seating, physical therapy, and orthotics to prevent or ameliorate the effects of scoliosis; special education; and assistive communication devices.

Keywords

Pelizaeus-Merzbacher disease - spastic paraplegia 2 - Pelizaeus-Merzbacher-like disease - spastic paraplegia 44

Corresponding Author Statement: MIM numbers refer to entries in Online Mendelian Inheritance in Man available at http://www.ncbi.nlm.nih.gov/omim/.

• References

• 1 Mimault C, Giraud G, Courtois V , et al; The Clinical European Network on Brain Dysmyelinating Disease. Proteolipoprotein gene analysis in 82 patients with sporadic Pelizaeus-Merzbacher disease: duplications, the major cause of the disease, originate more frequently in male germ cells, but point mutations do not. Am J Hum Genet 1999; 65 (2) 360-369
• 2 Woodward KJ, Cundall M, Sperle K , et al. Heterogeneous duplications in patients with Pelizaeus-Merzbacher disease suggest a mechanism of coupled homologous and nonhomologous recombination. Am J Hum Genet 2005; 77 (6) 966-987
• 3 Lee JA, Inoue K, Cheung SW, Shaw CA, Stankiewicz P, Lupski JR. Role of genomic architecture in PLP1 duplication causing Pelizaeus-Merzbacher disease. Hum Mol Genet 2006; 15 (14) 2250-2265
• 4 Regis S, Biancheri R, Bertini E , et al. Genotype-phenotype correlation in five Pelizaeus-Merzbacher disease patients with PLP1 gene duplications. Clin Genet 2008; 73 (3) 279-287
• 5 Shimojima K, Inoue T, Hoshino A , et al. Comprehensive genetic analyses of PLP1 in patients with Pelizaeus-Merzbacher disease applied by array-CGH and fiber-FISH analyses identified new mutations and variable sizes of duplications. Brain Dev 2010; 32 (3) 171-179
• 6 Hodes ME, Woodward K, Spinner NB , et al. Additional copies of the proteolipid protein gene causing Pelizaeus-Merzbacher disease arise by separate integration into the X chromosome. Am J Hum Genet 2000; 67 (1) 14-22
• 7 Inoue K, Osaka H, Thurston VC , et al. Genomic rearrangements resulting in PLP1 deletion occur by nonhomologous end joining and cause different dysmyelinating phenotypes in males and females. Am J Hum Genet 2002; 71 (4) 838-853
• 8 Shy ME, Hobson G, Jain M , et al. Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Ann Neurol 2003; 53 (3) 354-365
• 9 Hobson GM, Huang Z, Sperle K , et al. Splice-site contribution in alternative splicing of PLP1 and DM20: molecular studies in oligodendrocytes. Hum Mutat 2006; 27 (1) 69-77
• 10 Bonnet-Dupeyron MN, Combes P, Santander P, Cailloux F, Boespflug-Tanguy O, Vaurs-Barrière C. PLP1 splicing abnormalities identified in Pelizaeus-Merzbacher disease and SPG2 fibroblasts are associated with different types of mutations. Hum Mutat 2008; 29 (8) 1028-1036
• 11 Grossi S, Regis S, Biancheri R , et al. Molecular genetic analysis of the PLP1 gene in 38 families with PLP1-related disorders: identification and functional characterization of 11 novel PLP1 mutations. Orphanet J Rare Dis 2011; 6: 40
• 12 Wolf NI, Sistermans EA, Cundall M , et al. Three or more copies of the proteolipid protein gene PLP1 cause severe Pelizaeus-Merzbacher disease. Brain 2005; 128 (Pt 4) 743-751
• 13 Combes P, Bonnet-Dupeyron MN, Gauthier-Barichard F , et al. PLP1 and GPM6B intragenic copy number analysis by MAPH in 262 patients with hypomyelinating leukodystrophies: Identification of one partial triplication and two partial deletions of PLP1. Neurogenetics 2006; 7 (1) 31-37
• 14 Garbern J, Krajewski K. Hobson G, PLP1-related disorders. In: Pagon R, Bird T, Dolan C, Stephens K, , eds. GeneReviews. Seattle University of Washington: 1993. http://www.ncbi.nlm.nih.gov/books/NBK1182/ . Accessed September 29, 2011
• 15 Heim P, Claussen M, Hoffmann B , et al. Leukodystrophy incidence in Germany. Am J Med Genet 1997; 71 (4) 475-478
• 16 Seeman P, Krsck P, Namestkova K , et al. Pelizaeus-Merzbacher's disease (PMD) - Detection of the most frequent mutation of the proteolipid protein gene in Czech patients and families with the classical form of PMD. Ceska Slovenska Neurol Neurochir 2003; 66: 95-104
• 17 Abrams CK, Scherer SS. Gap junctions in inherited human disorders of the central nervous system. Biochim Biophys Acta 2011;
• 18 Uhlenberg B, Schuelke M, Rüschendorf F , et al. Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease. Am J Hum Genet 2004; 75 (2) 251-260
• 19 Salviati L, Trevisson E, Baldoin MC , et al. A novel deletion in the GJA12 gene causes Pelizaeus-Merzbacher-like disease. Neurogenetics 2007; 8 (1) 57-60
• 20 Wolf NI, Cundall M, Rutland P , et al. Frameshift mutation in GJA12 leading to nystagmus, spastic ataxia and CNS dys-/demyelination. Neurogenetics 2007; 8 (1) 39-44
• 21 Bugiani M, Al Shahwan S, Lamantea E , et al. GJA12 mutations in children with recessive hypomyelinating leukoencephalopathy. Neurology 2006; 67 (2) 273-279
• 22 Henneke M, Combes P, Diekmann S , et al. GJA12 mutations are a rare cause of Pelizaeus-Merzbacher-like disease. Neurology 2008; 70 (10) 748-754
• 23 Wang J, Wang H, Wang Y, Chen T, Wu X, Jiang Y. Two novel gap junction protein alpha 12 gene mutations in two Chinese patients with Pelizaeus-Merzbacher-like disease. Brain Dev 2010; 32 (3) 236-243
• 24 Combes P, Kammoun N, Monnier A , et al. Relevance of GJC2 promoter mutation in Pelizaeus-Merzbacher-like disease. Ann Neurol 2010; 71 (1) 146-148
• 25 Orthmann-Murphy JL, Salsano E, Abrams CK , et al. Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations. Brain 2009; 132 (Pt 2) 426-438
• 26 Ferrell RE, Baty CJ, Kimak MA , et al. GJC2 missense mutations cause human lymphedema. Am J Hum Genet 2010; 86 (6) 943-948
• 27 Boulloche J, Aicardi J. Pelizaeus-Merzbacher disease: clinical and nosological study. J Child Neurol 1986; 1 (3) 233-239
• 28 Hodes ME, Pratt VM, Dlouhy SR. Genetics of Pelizaeus-Merzbacher disease. Dev Neurosci 1993; 15 (6) 383-394
• 29 Cailloux F, Gauthier-Barichard F, Mimault C , et al; Clinical European Network on Brain Dysmyelinating Disease. Genotype-phenotype correlation in inherited brain myelination defects due to proteolipid protein gene mutations. Eur J Hum Genet 2000; 8 (11) 837-845
• 30 Garbern JY, Yool DA, Moore GJ , et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 2002; 125 (Pt 3) 551-561
• 31 Sistermans EA, de Coo RF, De Wijs IJ, Van Oost BA. Duplication of the proteolipid protein gene is the major cause of Pelizaeus-Merzbacher disease. Neurology 1998; 50 (6) 1749-1754
• 32 Fattal-Valevski A, DiMaio MS, Hisama FM , et al. Variable expression of a novel PLP1 mutation in members of a family with Pelizaeus-Merzbacher disease. J Child Neurol 2009; 24 (5) 618-624
• 33 Hurst S, Garbern J, Trepanier A, Gow A. Quantifying the carrier female phenotype in Pelizaeus-Merzbacher disease. Genet Med 2006; 8 (6) 371-378
• 34 Carvalho C, Bartnik M, Pehlivan D , et al. Evidence for disease penetrance relating to CNV size: Pelizaeus-Merzbacher disease and manifesting carriers with a familial 11 Mb duplication at Xq22. Clin Genet , in press
• 35 Nezu A, Kimura S, Takeshita S, Osaka H, Kimura K, Inoue K. An MRI and MRS study of Pelizaeus-Merzbacher disease. Pediatr Neurol 1998; 18 (4) 334-337
• 36 Plecko B, Stöckler-Ipsiroglu S, Gruber S , et al. Degree of hypomyelination and magnetic resonance spectroscopy findings in patients with Pelizaeus Merzbacher phenotype. Neuropediatrics 2003; 34 (3) 127-136
• 37 Steenweg ME, Vanderver A, Blaser S , et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain 2010; 133 (10) 2971-2982
• 38 Barkovich AJ. Magnetic resonance techniques in the assessment of myelin and myelination. J Inherit Metab Dis 2005; 28 (3) 311-343
• 39 Takanashi J, Inoue K, Tomita M , et al. Brain N-acetylaspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication. Neurology 2002; 58 (2) 237-241
• 40 Bonavita S, Schiffmann R, Moore DF , et al. Evidence for neuroaxonal injury in patients with proteolipid protein gene mutations. Neurology 2001; 56 (6) 785-788
• 41 Hobson GM, Huang Z, Sperle K, Stabley DL, Marks HG, Cambi F. A PLP splicing abnormality is associated with an unusual presentation of PMD. Ann Neurol 2002; 52 (4) 477-488
• 42 Hanefeld FA, Brockmann K, Pouwels PJ, Wilken B, Frahm J, Dechent P. Quantitative proton MRS of Pelizaeus-Merzbacher disease: evidence of dys- and hypomyelination. Neurology 2005; 65 (5) 701-706
• 43 Henneke M, Gegner S, Hahn A , et al. Clinical neurophysiology in GJA12-related hypomyelination vs Pelizaeus-Merzbacher disease. Neurology 2010; 74 (22) 1785-1789
• 44 Verlinsky Y, Rechitsky S, Laziuk K, Librach C, Genovese R, Kuliev A. Preimplantation genetic diagnosis for Pelizaeus-Merzbacher disease with testing for age-related aneuploidies. Reprod Biomed Online 2006; 12 (1) 83-88
• 45 Welch KO, Marin RS, Pandya A, Arnos KS. Compound heterozygosity for dominant and recessive GJB2 mutations: effect on phenotype and review of the literature. Am J Med Genet A 2007; 143A (14) 1567-1573
• 46 Feinstein M, Markus B, Noyman I , et al. Pelizaeus-Merzbacher-like disease caused by AIMP1/p43 homozygous mutation. Am J Hum Genet 2010; 87 (6) 820-828
• 47 Magen D, Georgopoulos C, Bross P , et al. Mitochondrial hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. Am J Hum Genet 2008; 83 (1) 30-42
• 48 Biancheri R, Zara F, Bruno C , et al. Hypomyelination and congenital cataract. In: Pagon R, Bird T, Dolan C, Stephens K, , eds. GeneReviews. Seattle: University of Washington; 1993. http://www.ncbi.nlm.nih.gov/books/NBK2587/ . Accessed September 29, 2011
• 49 Dempsey MA, Dumitrescu AM. Refetoff S, MCT8 (SLC16A2)-specific thyroid hormone cell transporter deficiency. In: Pagon R, Bird T, Dolan C, Stephens K, , eds. GeneReviews. Seattle: University of Washington; 1993. http://www.ncbi.nlm.nih.gov/books/NBK26373/ . Accessed September 29, 2011
• 50 Padiath QS, Saigoh K, Schiffmann R , et al. Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet 2006; 38 (10) 1114-1123
• 51 Adams D, Gahl WA. Free sialic acid storage disorders. In: Pagon R, Bird T, Dolan C, Stephens K, , eds. GeneReviews. Seattle: University of Washington; 1993. http://www.ncbi.nlm.nih.gov/books/NBK1470/ . Accessed September 29, 2011
• 52 Inoue K, Khajavi M, Ohyama T , et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet 2004; 36 (4) 361-369
• 53 Schrander-Stumpel C, Vos YJ. L1 Syndrome. In: Pagon R, Bird T, Dolan C, Stephens K, , eds. GeneReviews. Seattle: University of Washington; 1993. http://www.ncbi.nlm.nih.gov/books/NBK1484/ . Accessed September 29, 2011
• 54 Fink JK. Hereditary spastic paraplegia overview. In: Pagon R, Bird T, Dolan C, Stephens K, , eds. GeneReviews. Seattle: University of Washington; 1993. http://www.ncbi.nlm.nih.gov/books/NBK1509/ . Accessed September 29, 2011